Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Analyst Ratings
Moderate Buy
8 Buy
6 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
APLS Stock 12 Month Forecast
Average Price Target
$38.14
▲(51.17% Upside)
| Highest Price Target$117.80 | Average Price Target$38.14 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Buy
―
Reiterated
12/04/25
Buy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre PotentialWe believe the publication in a prestigious medical journal further validates the impressive efficacy demonstrated by and will be an important tool to drive awareness of Empaveli’s strong data in these indications in support of the ongoing launch. We also believe the strength of the data is highlighted in the accompanying editorial, in which the authors describe the reduction in proteinuria observed in VALIANT as “remarkable, given that 72% of participants were receiving active immunosuppressive therapy at enrollment”, while also calling for more and longer-term data.
Citi
$45→$117.8
Buy
366.90%
Upside
Reiterated
12/02/25
H.C. Wainwright
$19.81→$45
Buy
78.36%
Upside
Reiterated
11/14/25
J.P. Morgan
$40→$36
Buy
42.69%
Upside
Reiterated
11/05/25
Wolfe Research
―
Hold
―
Initiated
11/05/25
TD Cowen
$45
Buy
78.36%
Upside
Reiterated
11/04/25
Mizuho Securities
$24→$19
Hold
-24.69%
Downside
Reiterated
11/03/25
Robert W. Baird
$50→$52
Buy
106.10%
Upside
Reiterated
10/31/25
Needham
$29
Buy
14.94%
Upside
Reiterated
10/30/25
Resilient Revenue and Strategic Positioning Support Buy Rating for Apellis PharmaceuticalsWe estimate Syfovre holds ~55% (down from ~58% in 2Q25) revenue-based market share over Izervay. Mgmt reiterated cash on hand plus product sales is sufficient to get to sustainable profitability. This morning, Astellas significantly lowered their revenue forecast for ~$550M (was ~$750M), which we see as a negative readthrough to Syfovre and the overall GA market. That, coupled with the ongoing co-pay issues, is putting significant pressure on APLS shares today in our view.
RBC Capital
$22
Hold
-12.80%
Downside
Reiterated
10/30/25
Morgan Stanley
$26→$25
Hold
-0.91%
Downside
Reiterated
10/30/25
Bank of America Securities
$29→$27
Hold
7.02%
Upside
Reiterated
10/30/25
Wells Fargo
$29→$32
Buy
26.83%
Upside
Upgraded
10/15/25
Piper Sandler
$28
Hold
10.98%
Upside
Reiterated
10/06/25
Goldman Sachs
$18
Sell
-28.66%
Downside
Downgraded
09/26/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Buy
―
Reiterated
12/04/25
Buy Rating for Apellis Pharmaceuticals: Strong Empaveli Launch and Long-term Syfovre PotentialWe believe the publication in a prestigious medical journal further validates the impressive efficacy demonstrated by and will be an important tool to drive awareness of Empaveli’s strong data in these indications in support of the ongoing launch. We also believe the strength of the data is highlighted in the accompanying editorial, in which the authors describe the reduction in proteinuria observed in VALIANT as “remarkable, given that 72% of participants were receiving active immunosuppressive therapy at enrollment”, while also calling for more and longer-term data.
Citi
$45→$117.8
Buy
366.90%
Upside
Reiterated
12/02/25
H.C. Wainwright
$19.81→$45
Buy
78.36%
Upside
Reiterated
11/14/25
J.P. Morgan
$40→$36
Buy
42.69%
Upside
Reiterated
11/05/25
Wolfe Research
―
Hold
―
Initiated
11/05/25
TD Cowen
$45
Buy
78.36%
Upside
Reiterated
11/04/25
Mizuho Securities
$24→$19
Hold
-24.69%
Downside
Reiterated
11/03/25
Robert W. Baird
$50→$52
Buy
106.10%
Upside
Reiterated
10/31/25
Needham
$29
Buy
14.94%
Upside
Reiterated
10/30/25
Resilient Revenue and Strategic Positioning Support Buy Rating for Apellis PharmaceuticalsWe estimate Syfovre holds ~55% (down from ~58% in 2Q25) revenue-based market share over Izervay. Mgmt reiterated cash on hand plus product sales is sufficient to get to sustainable profitability. This morning, Astellas significantly lowered their revenue forecast for ~$550M (was ~$750M), which we see as a negative readthrough to Syfovre and the overall GA market. That, coupled with the ongoing co-pay issues, is putting significant pressure on APLS shares today in our view.
RBC Capital
$22
Hold
-12.80%
Downside
Reiterated
10/30/25
Morgan Stanley
$26→$25
Hold
-0.91%
Downside
Reiterated
10/30/25
Bank of America Securities
$29→$27
Hold
7.02%
Upside
Reiterated
10/30/25
Wells Fargo
$29→$32
Buy
26.83%
Upside
Upgraded
10/15/25
Piper Sandler
$28
Hold
10.98%
Upside
Reiterated
10/06/25
Goldman Sachs
$18
Sell
-28.66%
Downside
Downgraded
09/26/25
Best Analysts Covering Apellis Pharmaceuticals
1 Month
xxx
Success Rate
23/35 ratings generated profit
Average Return
+5.75%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.71% of your transactions generating a profit, with an average return of +5.75% per trade.
3 Months
xxx
Success Rate
22/35 ratings generated profit
Average Return
+2.39%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.86% of your transactions generating a profit, with an average return of +2.39% per trade.
1 Year
Success Rate
12/27 ratings generated profit
Average Return
-2.07%
reiterated a buy rating 11 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -2.07% per trade.
2 Years
xxx
Success Rate
15/29 ratings generated profit
Average Return
+2.59%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 51.72% of your transactions generating a profit, with an average return of +2.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
APLS Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
13
13
10
10
10
Buy
6
5
4
4
5
Hold
26
23
18
16
15
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
45
42
33
31
30
Each month's total comprises the sum of three months' worth of ratings.
APLS Financial Forecast
APLS Stock Forecast FAQ
What is APLS’s average 12-month price target, according to analysts?
Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is 38.14.
What is APLS’s upside potential, based on the analysts’ average price target?
Apellis Pharmaceuticals Inc has 51.17% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is APLS a Buy, Sell or Hold?
Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 6 hold ratings and 1 sell ratings.
What is Apellis Pharmaceuticals Inc’s price target?
The average price target for Apellis Pharmaceuticals Inc is 38.14. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $117.80 ,the lowest forecast is $18.00. The average price target represents 51.17% Increase from the current price of $25.23.
The highest analyst price target is $117.80 ,the lowest forecast is $18.00. The average price target represents 51.17% Increase from the current price of $25.23.
What do analysts say about Apellis Pharmaceuticals Inc?
Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of APLS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.